Millennium/Takeda’s Phase III IBD Drug Promises Improved Safety
This article was originally published in The Pink Sheet Daily
Executive Summary
Trials in Crohn’s disease and ulcerative colitis are going with plans for filing in both indications. Meanwhile, Takeda’s blockbuster GI drug Prevacid goes generic in May.
You may also be interested in...
Takeda Files Selective Intregrin Antagonist Vedolizumab For IBD
Takeda’s drug is in the same family as Biogen Idec’s Tysabri, but is more selective and theoretically safer; no PML cases have been reported for vedolizumab in trials to date. Roche and Pfizer also have different kinds of selective integrin antagonists in development for IBD.
Takeda Files Selective Intregrin Antagonist Vedolizumab For IBD
Takeda’s drug is in the same family as Biogen Idec’s Tysabri, but is more selective and theoretically safer; no PML cases have been reported for vedolizumab in trials to date. Roche and Pfizer also have different kinds of selective integrin antagonists in development for IBD.
Takeda Files Selective Intregrin Antagonist Vedolizumab For IBD
Takeda’s drug is in the same family as Biogen Idec’s Tysabri, but is more selective and theoretically safer; no PML cases have been reported for vedolizumab in trials to date. Roche and Pfizer also have different kinds of selective integrin antagonists in development for IBD.